Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance.
about
When prostate cancer remains undetectable: The dilemmaThe role of magnetic resonance imaging in the diagnosis and management of prostate cancerActive surveillance for prostate cancer: current evidence and contemporary state of practiceCan contemporary patients with biopsy Gleason score 3+4 be eligible for active surveillance?5-α reductase inhibitors and prostate cancer prevention: where do we turn now?Targeted prostate biopsy in select men for active surveillance: do the Epstein criteria still apply?Standards for prostate biopsy.Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH databaseFocal therapy of prostate cancer: evidence-based analysis for modern selection criteria.Impact of immediate TRUS rebiopsy in a patient cohort considering active surveillance for favorable risk prostate cancer.Active surveillance in men with low-risk prostate cancer: current and future challenges.A multi-institutional evaluation of active surveillance for low risk prostate cancer.Evaluation of prediction models for the staging of prostate cancer.Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy.TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer.Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.Automatic classification of prostate cancer Gleason scores from multiparametric magnetic resonance images.Predictive models for worsening prognosis in potential candidates for active surveillance of presumed low-risk prostate cancer.Validation of Selection Criteria for Active Surveillance in Prostate Cancer.Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancerSerial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: Incremental ValueActive surveillance for prostate cancerTiming of curative treatment for prostate cancer: a systematic review.Localization of higher grade tumor foci in potential candidates for active surveillance who opt for radical prostatectomy.Imaging modalities for prostate cancer.The presence of primary circulating prostate cells is associated with upgrading and upstaging in patients eligible for active surveillanceEffect of the number of biopsy cores on prostate cancer detection and staging.Performance of multiparametric magnetic resonance imaging in the evaluation and management of clinically low-risk prostate cancerProstate saturation biopsy following a first negative biopsy: state of the art.Interpretation and reporting multiparametric prostate MRI: a primer for residents and novices.Active surveillance for low-risk prostate cancer: diversity of practice across Europe.Early experience with active surveillance in low-risk prostate cancer treated.Expectant management for men with early stage prostate cancer.Standard and Targeted Biopsy During Follow-up for Active Surveillance.Primary Gleason pattern upgrading in contemporary patients with D'Amico low-risk prostate cancer: implications for future biomarkers and imaging modalities.Image-based monitoring of targeted biopsy-proven prostate cancer on active surveillance: 11-year experience.Are magnetic resonance imaging undetectable prostate tumours clinically significant? Results of histopathological analyses.PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER.The importance of active surveillance, and immediate re-biopsy in low-risk prostate cancer: The largest series from TurkeyValue of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
P2860
Q26795515-395EF210-6604-4A3D-81FE-A228FAE64DE5Q26849794-D636FE42-7DF1-4665-B542-1BDC88892BC7Q28066534-AE1B3063-C264-4712-BF53-2B33E10E1F3AQ28543448-E123CC52-011D-4FA1-BAC5-3D5A88661FF9Q34020127-5DFEB1D2-2DE2-4906-A5B0-9F1AFFEF255BQ34032598-5D13C0EE-6F7F-4526-89CC-C528632FA74EQ34079923-70C632A7-78A6-4043-B86B-31A4C31A0647Q34127059-C50393C0-2136-4676-9294-55094D26358DQ34148722-048ECAE4-E523-4F11-ACCB-A5485E788FBFQ34406115-E8B14E59-5525-4D6D-B12D-29CA2138E5B4Q34448113-0CE9D622-978C-4C7D-BF1C-EA6FDA00E5E3Q34541484-BEA72C12-6011-49AF-9364-E667E0E42977Q35044520-22FA756A-0735-4C65-86EE-DFFB36035BF9Q35235435-522C19F6-2A08-403F-B3E5-91D49B1BBB67Q35780014-82DFE2AB-C57F-417D-A57D-6964F773B71DQ35806400-51A2432A-9756-4EC4-9479-A007598E9DB6Q36306100-C69489D0-D5D8-4C74-9E67-6273DB4F5602Q36757440-D2BC235E-584F-4F00-859D-4991D1BFA60EQ36898971-D3B97CA0-10FE-48E2-98E2-82CE10D48800Q36928846-2B4A4BEA-8BF3-42D3-AA59-86E6E7EA47A1Q36988608-E48B4BDB-2C9E-4D40-9625-F4B31CB8FF62Q37138594-36321B43-52CF-4F48-A51C-8A51DDDF9F55Q37201922-8918B843-0CF9-474A-A1AA-B6738763427BQ37427720-E145500F-108A-4C68-81E6-79B0EEC91C91Q37546036-43CBE1BC-00D6-4E18-B3E1-7D19CF20A6D4Q37592409-1397C9E1-CDC5-4539-BE87-DAFC974EBB88Q37707378-C6F6D99E-F603-4E82-8E9F-74F71DE771DBQ37709638-D5FA13D6-4E17-46DB-A633-DD06C88D202DQ38027698-F3DAEF9B-D60C-40E5-B4FD-880C07132878Q38190885-25CDE4F8-FF34-45B0-96E0-D4643566DC6CQ38197935-B134D862-C429-4ED5-B07D-29B5F9069E72Q38306089-6DB25B34-CEDD-476F-9E19-6FC43C2B131FQ38469754-AC13B3C1-4708-4341-B132-109F1960A5DAQ38843915-15AE16F7-CDC0-49E9-8391-3B9D034835FFQ38846321-E5D21BB2-DA68-4F6A-812C-6A08F24359B1Q38993533-FD246B09-702A-42B7-B432-A3A2500CC19BQ39024065-72A13D7C-FBE9-4352-94E9-F382798800A2Q39108592-C8814257-6F88-4059-B27B-10EE0F5F4C43Q39382734-6FD3CEBA-8FC6-4D2E-BD6F-265C724BD8C3Q39513641-E82A598B-97FB-4DE4-9060-058B1036ED80
P2860
Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pathological upgrading and up ...... gible for active surveillance.
@en
Pathological upgrading and up ...... gible for active surveillance.
@nl
type
label
Pathological upgrading and up ...... gible for active surveillance.
@en
Pathological upgrading and up ...... gible for active surveillance.
@nl
prefLabel
Pathological upgrading and up ...... gible for active surveillance.
@en
Pathological upgrading and up ...... gible for active surveillance.
@nl
P2093
P2860
P1476
Pathological upgrading and up ...... gible for active surveillance.
@en
P2093
Bertrand D Guillonneau
James A Eastham
Kinjal C Vora
Ryan K Berglund
Scott E Eggener
Timothy A Masterson
P2860
P304
1964-7; discussion 1967-8
P356
10.1016/J.JURO.2008.07.051
P407
P577
2008-09-17T00:00:00Z